Personalized vaccine therapy combined with anti-PD-1 treatment for head and neck cancer

Who could benefit from this research

What this research studies

This research investigates a new treatment approach for patients with recurrent or metastatic squamous cell carcinoma of the head and neck by combining personalized vaccine immunotherapy with anti-PD-1 antibodies. The therapy aims to enhance the immune response against tumors by using a vaccine made from the patient's own tumor cells, which is designed to stimulate the immune system more effectively. By tailoring the vaccine to the unique characteristics of each patient's cancer, the researchers hope to improve treatment outcomes for those who do not respond well to existing therapies. The study will involve creating tumor membrane vesicles that present specific tumor antigens alongside immunostimulatory molecules to boost the anti-tumor immune response.

Why it matters

Where this research is happening

• Emory University
  Atlanta, United States Active

Researchers

• Principal investigator: Shin, Dong M — Emory University
• Study coordinator: Shin, Dong M

Related research

Other NIH-funded projects on the same topics.

• Hypoxia and metabolism as targets to improve immunotherapy in head and neck cancer

  This grant tests new combinations of metabolic drugs with immunotherapy to help people with head and neck cancer respond better to treatment.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11404946

• Biomarker test to predict immunotherapy response in head and neck cancer

  A multi-site study aims to validate blood-based and immune biomarkers to predict which head and neck cancer patients will respond to immunotherapy.

  NIH research Dartmouth College · Hanover, United States · NIH-11342927

• Personalized vaccine plus anti-PD-1 for recurrent or metastatic head and neck cancer

  A personalized vaccine made from each patient's tumor is combined with anti‑PD‑1 immunotherapy for adults with recurrent or metastatic head and neck cancer.

  NIH research Emory University · Atlanta, United States · NIH-11300175

• Targeting low oxygen and abnormal metabolism to help immunotherapy work better in head and neck cancer

  This research tests whether changing tumor oxygen levels and metabolism can help immunotherapy work better for people with recurrent or metastatic head and neck cancer.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11192275

• Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe

  A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11625534

• Oral cancer recurrence predictor using tumor microbes and gene activity

  This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11591548

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.